Literature DB >> 32573995

Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.

Graziella Bonetti1, Filippo Manelli2, Andrea Patroni3, Alessandra Bettinardi1, Gianluca Borrelli1, Gianfranco Fiordalisi1, Antonio Marino1, Annamaria Menolfi1, Sara Saggini1, Roberta Volpi1, Adriano Anesi4, Giuseppe Lippi5.   

Abstract

Background Comprehensive information has been published on laboratory tests which may predict worse outcome in Asian populations with coronavirus disease 2019 (COVID-19). The aim of this study is to describe laboratory findings in a group of Italian COVID-19 patients in the area of Valcamonica, and correlate abnormalities with disease severity. Methods The final study population consisted of 144 patients diagnosed with COVID-19 (70 who died during hospital stay and 74 who survived and could be discharged) between March 1 and 30, 2020, in Valcamonica Hospital. Demographical, clinical and laboratory data were collected upon hospital admission and were then correlated with outcome (i.e. in-hospital death vs. discharge). Results Compared to patients who could be finally discharged, those who died during hospital stay displayed significantly higher values of serum glucose, aspartate aminotransferase (AST), creatine kinase (CK), lactate dehydrogenase (LDH), urea, creatinine, high-sensitivity cardiac troponin I (hscTnI), prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (APTT), D-dimer, C reactive protein (CRP), ferritin and leukocytes (especially neutrophils), whilst values of albumin, hemoglobin and lymphocytes were significantly decreased. In multiple regression analysis, LDH, CRP, neutrophils, lymphocytes, albumin, APTT and age remained significant predictors of in-hospital death. A regression model incorporating these variables explained 80% of overall variance of in-hospital death. Conclusions The most important laboratory abnormalities described here in a subset of European COVID-19 patients residing in Valcamonica are highly predictive of in-hospital death and may be useful for guiding risk assessment and clinical decision-making.

Entities:  

Keywords:  COVID-19; coronavirus disease 2019; laboratory medicine; laboratory tests

Mesh:

Substances:

Year:  2020        PMID: 32573995     DOI: 10.1515/cclm-2020-0459

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  40 in total

1.  Skeletal Muscle Manifestations and Creatine Kinase in COVID-19.

Authors:  Sarah A Friedman; Zeinab Charmchi; Michael Silver; Nuri Jacoby; Jonathan Perk; Yaacov Anziska
Journal:  Neurohospitalist       Date:  2022-06-01

2.  Development of a Mortality Prediction Model in Hospitalised SARS-CoV-2 Positive Patients Based on Routine Kidney Biomarkers.

Authors:  Anna N Boss; Abhirup Banerjee; Michail Mamalakis; Surajit Ray; Andrew J Swift; Craig Wilkie; Joseph W Fanstone; Bart Vorselaars; Joby Cole; Simonne Weeks; Louise S Mackenzie
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

3.  Correlates of In-Hospital COVID-19 Deaths: A Competing Risks Survival Time Analysis of Retrospective Mortality Data.

Authors:  Ashish Goel; Alpana Raizada; Ananya Agrawal; Kamakshi Bansal; Saurabh Uniyal; Pratima Prasad; Anil Yadav; Asha Tyagi; R S Rautela
Journal:  Disaster Med Public Health Prep       Date:  2021-03-25       Impact factor: 1.385

4.  IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid.

Authors:  Encarnación Donoso-Navarro; Ignacio Arribas Gómez; Francisco A Bernabeu-Andreu
Journal:  Biomark Insights       Date:  2021-05-24

5.  A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic.

Authors:  Hyung-Jun Kim; Hyeontaek Hwang; Hyunsook Hong; Jae-Joon Yim; Jinwoo Lee
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

6.  Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment.

Authors:  Luis Sarabia De Ardanaz; Jose M Andreu-Ubero; Miriam Navidad-Fuentes; Miguel Ángel Ferrer-González; Victor Ruíz Del Valle; Inmaculada Salcedo-Bellido; Rocío Barrios-Rodríguez; Rafael Cáliz-Cáliz; Pilar Requena
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 7.  Comparison of the cardiovascular presentations, complications and outcomes following different coronaviruses' infection: A systematic review.

Authors:  Mohammad Mostafa Ansari Ramandi; Hossein Yarmohammadi; Somayeh Beikmohammadi; Behzad Hassan Hosseiny Fahimi; Farbod Hatami; Hossein Beydokhti; Hooman Bakhshandeh; Nasim Naderi
Journal:  J Cardiovasc Thorac Res       Date:  2021-04-24

Review 8.  Predicting clinical outcomes among hospitalized COVID-19 patients using both local and published models.

Authors:  William Galanter; Jorge Mario Rodríguez-Fernández; Kevin Chow; Samuel Harford; Karl M Kochendorfer; Maryam Pishgar; Julian Theis; John Zulueta; Houshang Darabi
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-24       Impact factor: 2.796

9.  Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis.

Authors:  Farha Musharrat Noor; Md Momin Islam
Journal:  J Community Health       Date:  2020-12

10.  Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.

Authors:  Robert W Cross; Krystle N Agans; Abhishek N Prasad; Viktoriya Borisevich; Courtney Woolsey; Daniel J Deer; Natalie S Dobias; Joan B Geisbert; Karla A Fenton; Thomas W Geisbert
Journal:  Res Sq       Date:  2020-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.